Alvotech (ALVO) files first known Eylea 8 mg biosimilar application...

added blog Other

2026-10-23 22:16:07 - Translate -

Alvotech (ALVO) files first known Eylea 8 mg biosimilar application in Europe

Alvotech and Advanz Pharma sent AVT29 to the European Medicines Agency on 14 October 2026 as a line extension to Mynzepli, the Eylea 2 mg biosimilar. Alvotech (ALVO) and its partner Advanz Pharma submitted AVT29 to the European Medicines Agency on 14 October 2026, according to a company release issued the same day. AVT29 is a proposed biosimilar to Eylea 8 mg, the higher-dose form of...

0 Comments 0 Shares 5 Views 0 Reviews